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Abstract
Enteroviruses are frequent aetiological agents of central nervous system infections in humans. In 2000 and 2005, two large outbreaks of
Echovirus 30 (a member of species human enterovirus B) were observed in the University Hospitals of Marseilles (France). Between the
two epidemics, the diagnostic protocols for enterovirus infection were modiﬁed, moving from viral cultures and classic RT-PCR in 2000
to real-time RT-PCR in 2005. We compared some viral and epidemiological characteristics of the 2000 and 2005 outbreaks with special
attention to diagnostic procedures and to the subsequent clinical management of patients. Despite similar virological and epidemiological
characteristics during both outbreaks, our results show that real-time RT-PCR techniques used in 2005 noticeably shortened the period
of time necessary to deliver diagnostic results and suggest that this was associated with a decrease in the duration of hospitalization for
positive cases. In conclusion, this study suggests that the improvement of enterovirus diagnosis had a major ﬁnancial impact on the man-
agement of the 2005 epidemic in Marseilles and may constitute an interesting example of how new diagnostic methods in microbiology
can be self-ﬁnanced through improvement in patient management.
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Introduction
The enteroviruses (EVs) are a genus of the family Picornaviridae
which includes six species (representing over 70 serotypes)
isolated from man: human enteroviruses A–E (HEV-A–HEV-E)
and polioviruses [1]. During human infection, EVs which nor-
mally replicate in the intestinal tract may spread to other
organs, and in particular to the central nervous system.
Accordingly, EVs are the most frequent causes of aseptic
meningitis in both paediatric [2] and adult [3] populations. In
temperate regions, EVs circulate widely and cause seasonal
epidemics of meningitis in the summer and autumn with
sporadic cases during inter-epidemic periods [4]. Severe
presentations (meningoencephalitis, encephalitis and polyradi-
culoneuritis) can be encountered, particularly in neonates,
immunocompromised patients or patients with pre-existing
medical conditions or underlying illnesses. However, in the
vast majority of cases the disease is mild and self limiting, with
a large number of asymptomatic or pauci-symptomatic infec-
tions [1]. No antiviral treatment is currently available and vac-
cination is not used against EVs other than polioviruses,
because of the multiplicity of the antigenic types implicated in
human infections and the lack of cross-reactive immunity.
During the past decades, echovirus 30 (EV-30), a member
of the species human enterovirus B (HEV-B), has been respon-
sible for meningitis outbreaks with increasing frequency.
More speciﬁcally, large outbreaks were observed at the Uni-
versity Hospitals of Marseilles (France) in 2000 [5] and 2005.
Interestingly, an important change in the management of hos-
pitalized EV-infected patients occurred between the two epi-
demics: in 2000, the laboratory diagnosis of EV infections
was mainly based on viral cultures and partially on classic
RT-PCR ampliﬁcation, while in 2005 virus detection was
mainly achieved using a real-time RT-PCR technique. In the
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present study, we compare some viral and epidemiological
characteristics of the 2000 and 2005 outbreaks with special
attention given to the period of time necessary to deliver




Population studied. During the 2000 and 2005 outbreaks, 195
and 387 cerebrospinal ﬂuid (CSF) samples from patients with
clinical presentations suggesting EV infection were analysed.
All patients were hospitalized in the University Hospitals of
Marseilles, France.
Deﬁnition of conﬁrmed cases. As previously proposed and dis-
cussed [5], conﬁrmed cases of EV nervous system involve-
ment were deﬁned by the presence of (i) signs of meningeal
irritation and/or other central nervous system involvement
and/or febrile polyradiculoneuritis and (ii) positive culture or
RT-PCR in CSF.
Laboratory diagnosis
Diagnosis of EV infection. Diagnosis was achieved using (i)
inoculation of CSF samples onto human lung embryonic
ﬁbroblast MRC5 and continuous kidney Buffalo green mon-
key (BGM) cell lines (2000 and 2005 outbreak patients), (ii)
classic RT-PCR using the Enterovirus Consensus kit (Argene,
Verniolle, France) (2000 outbreak patients) and (iii) a real-
time RT-PCR method adapted from Watkins-Riedel et al. [6]
(2005 outbreak patients).
Genetic characterization of EVs. Genetic identiﬁcation of sero-
types was accomplished with cell culture isolates. During the
2000 outbreak, a ﬁrst screening used restriction fragment
length polymorphism (RFLP) analysis of PCR amplicons [7]
for the identiﬁcation of isolates closely related to the domi-
nant EV-30 strain. A number of these EV-30 isolates and all
isolates with different RFLP proﬁles were subsequently char-
acterized by sequencing. A 785-bp PCR product located in
the VP1 gene was synthesized and sequenced as reported
previously [5], and then compared with a reference VP1
database for serotype determination [8]. In 2005, all isolates
were sequenced using this method.
For the analysis of EV-30 isolates, sequences obtained
from cell culture isolates were combined with a choice of
relevant EV-30 VP1 sequences retrieved from the GenBank
database and aligned using the CLUSTALW programme [9]. Phy-
logenetic analysis was performed with MEGA version 3.1
[10] using the Kimura 2-parameter algorithm for distance
calculation and the Neighbor-Joining method for tree
construction. An EV-21 sequence (China 1999, GenBank
accession number AB268240) was used as an outgroup.
Results
Diagnosis of EV infection and viral characteristics of con-
ﬁrmed cases
In 2000, all samples (n = 195) were tested using cell culture
and 106 were also tested using RT-PCR. A total of 139 con-
ﬁrmed cases was identiﬁed: 22 cases were detected using
classic RT-PCR only, 70 using cell culture only and 47 using
both methods. Among 117 isolates from conﬁrmed cases, 95
were EV-30 (81%) and 22 belonged to other serotypes of
HEV-B (19%). Thirty-one isolates of EV-30 were further
characterized by sequencing of the VP1 gene sequence.
In 2005, 186 conﬁrmed cases were identiﬁed, mainly using
real-time RT-PCR and 24 isolates were obtained from these
samples. The VP1 region of these isolates was sequenced
and corresponded to 18 EV-30 (82%) and six isolates from
other serotypes of HEV-B (18%). In all cases, viruses isolated
in cell culture were also detected using real-time RT-PCR.
A total of 49 EV-30 VP1 sequences was obtained for analy-
sis (31 strains from 2000 and 18 from 2005). A phylogenetic
reconstruction is shown in Fig. 1. The tree indicates that all
VP1 genes of 2000 and 2005 EV-30 strains were closely
related and had a recent common ancestor. They belonged to
a unique recent lineage identiﬁed by a 99% bootstrap
resampling value. Genetic pairwise distances within this lineage
were lower than 5%; in comparison, the genetic variability
among all EV-30 isolates included in our tree was
approximately 15%. Isolates from 2000 were organized as
two distinct (but closely related) clusters (denoted 2000a and
2000b in Fig. 1). Isolates from 2005 belonged to a unique clus-
ter which appeared as a sister group to the 2000b cluster.
Epidemiological characteristics of conﬁrmed cases
The distribution of conﬁrmed cases by age group was similar
during the 2000 and 2005 outbreaks (Fig. 2). The median age
was 11.2 years in 2000 and 10.0 in 2005, with a majority of
conﬁrmed cases occurring in patients younger than 15 years.
The gender ratio (M/F) was 1.6 in 2000 and 1.4 in 2005.
Period of time necessary to deliver diagnostic results
In 2000, the mean time necessary for providing results to cli-
nicians was 12.4 ± 4.3 days, i.e. 11.6 ± 3.9 days in the case
of positive results (n = 139) and 14.3 ± 5.3 days in the case
of negative results (n = 56). The average delay was
652 Clinical Microbiology and Infection, Volume 16 Number 6, June 2010 CMI
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 651–656
No claim to original US government works
8.9 ± 4.2 days for classic RT-PCR results, i.e. 9.3 ± 4.5 days
for positive results (n = 69) and 8.1 ± 3.6 days for negative
results (n = 37). In 2005, all results were provided using the
real-time RT-PCR assay. The mean time necessary for pro-
viding results to clinicians was 1.9 ± 0.8 days, similar for
positive (n = 186) and negative results (n = 201).
Length-of-hospital stay
In 2000 and 2005, the mean lengths-of-hospital stay (LOS) in
conﬁrmed cases were 5.4 ± 4.8 days and 2.2± 1.8 days,
respectively. This difference is signiﬁcant (Student’s test), i.e.
hospitalizations were signiﬁcantly shorter in 2005.
Discussion
Numerous previous studies have tried to model and docu-
ment the clinical and economic impact of EV PCR diagnosis.
Differentiating EV positive and negative patients is important
[11–14] as the recommended treatments and the cost
related to LOS or diagnostic and therapeutic interventions
are different. A convergent line of arguments also suggests
that results must be available early in the management of
patients to impact signiﬁcantly on patient care in the
subgroup of EV-infected patients [12,15–17]. However, this
FIG. 1. Genetic relationship between 2000
and 2005 EV-30 isolates. The phylogenetic tree
was built using Kimura 2-parameter algorithm
and the Neighbor-Joining method. Bootstrap
resampling values (500 replications) are
indicated at main nodes. Abbreviations: AUS,
Australia; BLR, Byelorussia; CAN, Canada;
CHN, China; DEU, Germany; DNK, Denmark;
EST, Estonia; FIN, Finland; FRA, France; GEO,
Georgia; ISR, Israel; ITA, Italia; JAM, Jamaica;
JPN, Japan; MRS, Marseilles (France); NLD, the
Netherlands; PHL, Philippines; POL, Poland;
TWN, Taiwan; USA, United States of America.
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is intrinsically difﬁcult to evaluate as, in any given study, it is
not easy to establish that the groups of patients receiving
either early or delayed diagnosis are comparable. Indeed,
previously published studies have not provided precise infor-
mation on the clinical, epidemiological and virological charac-
terization of these groups.
The two successive enterovirus epidemics observed in
Marseilles in 2000 and 2005 offered an interesting opportu-
nity for a comparative study including a large number of
patients. Analysis of the two outbreaks showed that the epi-
demiological characteristics of the patients were similar (age
and gender ratio) and that, in both cases, a large majority of
cases were a result of infection by EV-30 (over 80%). In addi-
tion, genetic analysis of the VP1 gene of several EV-30 iso-
lates from 2000 and 2005 suggested that predominant strains
that circulated during these two outbreaks were genetically
closely related. Therefore, the characteristics of the patient
management could have been expected to be very similar on
both occasions.
However, we observed that the average duration of hospi-
talization of conﬁrmed cases was signiﬁcantly shorter in 2005
than in 2000. This had important direct ﬁnancial implications.
The overall direct cost of hospitalization at the University
Hospitals of Marseilles during the 2000 EV outbreak has been
estimated previously to be 541 EUR per patient per day [5].
Using this value for the calculation of costs, we could evaluate
the cost of hospitalization of the 186 conﬁrmed cases in 2005
at 221 377 EUR, using the actual average duration of hospital-
ization observed in 2005 (i.e. 2.2 days), and at 543 380 EUR,
using the average duration of hospitalization observed in 2000
(i.e. 5.4 days). In other words, decreasing LOS from 5.4 to
2.2 days in the group of conﬁrmed cases allowed us to save
approximately 322 000 EUR.
A retrospective analysis of the characteristics of the 2000
and 2005 epidemics revealed that a major change in the
management of virological diagnosis occurred between the
two outbreaks. In 2000, diagnosis relied mainly on cell cul-
tures inoculated with CSF samples. Using that technique, the
mean time necessary for providing results to clinicians was
12.4 ± 4.8 days (in particular, negative results could not be
delivered before 14–17 days). Only about half the samples
received were tested using classic RT-PCR and, even in this
case, the average delay was 8.9 days, reaching 9.3 days for
positive results (which were systematically double checked
to avoid false-positive results because of PCR contamina-
tion). As a result, the mean time for obtaining a positive
result from the laboratory (approximately 10 days) was
longer than the average time of hospitalization of conﬁrmed
cases. Consequently, the aetiological diagnosis was obtained
most of the time after the patient’s discharge and recovery.
In contrast, during the 2005 epidemic, all positive diagnoses
were delivered to the clinicians on the basis of the result of
real-time RT-PCR. This technology allowed very rapid provi-
sion of results and, in particular, did not require the veriﬁca-
tion of positive results. As a result, the mean time for
obtaining a diagnosis in 2005 dropped to 1.9 days and was
similar for both negative and positive results. Importantly, it
became shorter than the average duration of hospitalization
of conﬁrmed cases (2.2 ± 1.8 days). It can also be observed
that the rapid availability of the diagnostic results was
associated with an increase in demand: in 2000: 139 out of
195 samples (71%) were positive vs. 186 out of 387 (48%) in
2005, indicating that clinicians had spontaneously extended
the indications for EV diagnosis.
It is not possible to infer from this observation a direct
cause and effect relationship between the improvement of
FIG. 2. Percentage distribution of conﬁrmed
cases by age groups during the 2000 and 2005
enterovirus outbreaks.
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the aetiological diagnosis and the shortening of the average
time of hospitalization. Other factors, such as subtle differ-
ences in the virulence of the viruses or the effect of the
experience acquired during the ﬁrst outbreak, might be
invoked partially to account for modiﬁcations in patient
management. However, the hypothesis that obtaining an
early diagnosis of EV infections has played a signiﬁcant role
in reducing LOS is highly plausible. This assumption was
reinforced by interviews with clinicians in charge of hospi-
talized EV-infected patients, who conﬁrmed that obtaining a
rapid positive diagnosis of EV infection modiﬁed the man-
agement of patient care. Patients, or relatives of young
patients, suffering from enterovirus meningitides could
receive early reassuring information, unnecessary antibiotic
or anti-herpetic treatments could be stopped earlier and,
importantly, the absence of severe presentations associated
with a biological diagnosis of EV infection allowed patients
to be discharged earlier.
The authors are aware of some weaknesses in the pres-
ent study. It was not possible to be certain of the compa-
rability of the groups studied, although we can advance a
number of epidemiological and virological arguments to sup-
port this. The retrospective evaluation of clinical cases
explains the absence of several important parameters (e.g.
the avoidance of antibiotic or antiviral treatments or reduc-
tion in the duration of administration, the reduction in
radiological investigations, the reduction in nosocomial
infections (1) and ﬁnally the reduction in global cost for
hospitalized EV-infected patients). Similar methodological
problems were encountered in previously published studies.
However, a number of investigations have also tried to
evaluate some of these parameters prospectively[13,17].
Overall the results have suggested that obtaining an early
aetiological diagnosis by molecular methods permits health-
care services to shorten the duration of hospitalization, and
also to decrease unnecessary diagnostic and therapeutic
interventions, and consequently to reduce signiﬁcantly the
global cost of the clinical management of hospitalized EV-
infected patients. However, it is clear that savings are more
signiﬁcant when the proportion of positive EV diagnoses is
high, i.e. in the context of EV outbreaks or during the sea-
sonal period of sustained EV circulation.
In conclusion, our study of two successive important EV
outbreaks in southeast France supports previously pub-
lished studies which suggested an important impact of
enteroviral rapid molecular diagnosis on patient manage-
ment and resultant health care savings. In the speciﬁc con-
text of our study, the cost of the molecular diagnosis
using real-time RT-PCR, despite an increase in requests for
aetiological diagnosis, represented only a small percentage
of the saving achieved by the implementation of rapid
molecular testing. This constitutes a modest but interesting
example of how new diagnostic methods in microbiology
can be self-ﬁnanced through the improvement of patient
management.
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